JPMorgan Chase & Co. Has $38.96 Million Stock Holdings in REGENXBIO Inc. $RGNX

JPMorgan Chase & Co. grew its holdings in REGENXBIO Inc. (NASDAQ:RGNX) by 4.8% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 4,037,248 shares of the biotechnology company’s stock after purchasing an additional 185,223 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.08% of REGENXBIO worth $38,959,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. State of Alaska Department of Revenue bought a new stake in REGENXBIO during the third quarter worth approximately $25,000. Aquatic Capital Management LLC bought a new stake in shares of REGENXBIO in the third quarter valued at approximately $37,000. Jones Financial Companies Lllp grew its stake in shares of REGENXBIO by 44.4% in the third quarter. Jones Financial Companies Lllp now owns 4,133 shares of the biotechnology company’s stock worth $40,000 after acquiring an additional 1,270 shares during the last quarter. Steward Partners Investment Advisory LLC grew its stake in shares of REGENXBIO by 754.1% in the second quarter. Steward Partners Investment Advisory LLC now owns 5,663 shares of the biotechnology company’s stock worth $46,000 after acquiring an additional 5,000 shares during the last quarter. Finally, Captrust Financial Advisors bought a new position in REGENXBIO during the second quarter worth $85,000. Institutional investors and hedge funds own 88.08% of the company’s stock.

Insider Buying and Selling at REGENXBIO

In related news, insider Steve Pakola sold 5,124 shares of the company’s stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $10.35, for a total value of $53,033.40. Following the sale, the insider owned 247,926 shares of the company’s stock, valued at $2,566,034.10. The trade was a 2.02% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 12.79% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of REGENXBIO in a report on Thursday, January 22nd. Leerink Partners boosted their price objective on shares of REGENXBIO from $16.00 to $20.00 and gave the stock an “outperform” rating in a report on Monday, December 15th. HC Wainwright cut their price objective on shares of REGENXBIO from $32.00 to $30.00 and set a “buy” rating for the company in a research report on Monday, March 9th. Stifel Nicolaus increased their target price on shares of REGENXBIO from $40.00 to $45.00 and gave the company a “buy” rating in a research note on Friday, December 19th. Finally, Chardan Capital decreased their target price on REGENXBIO from $52.00 to $50.00 and set a “buy” rating on the stock in a research report on Tuesday, February 10th. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $27.50.

REGENXBIO Price Performance

Shares of RGNX stock opened at $8.10 on Friday. REGENXBIO Inc. has a one year low of $5.03 and a one year high of $16.19. The stock has a fifty day moving average price of $10.39 and a 200 day moving average price of $11.43. The stock has a market cap of $418.04 million, a P/E ratio of -2.15 and a beta of 1.08.

REGENXBIO (NASDAQ:RGNX) last announced its quarterly earnings results on Thursday, March 5th. The biotechnology company reported ($1.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.01) by ($0.29). REGENXBIO had a negative net margin of 113.75% and a negative return on equity of 103.12%. The business had revenue of $30.34 million during the quarter, compared to the consensus estimate of $45.48 million. Equities research analysts anticipate that REGENXBIO Inc. will post -4.84 EPS for the current year.

REGENXBIO Company Profile

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.